Traduction de «situ breast cancer amongst women » (Français → Néerlandais) :

Table 20 : Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)
Table 20: Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)

D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 without breast cancer from 54
individual data on 53 297 women with breast cancer and 100 239 without breast cancer from 54 epidemiological studies. Lancet

12. Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?
11. Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Breast cancer (age group 40 - 49) : observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)
Breast cancer (age group 40 - 49): observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)

Table 11: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 22 Study ID study
Table 9: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 21 Study ID study

56. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.
57. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.

13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.